Legal & General Group Plc Buys 12,736 Shares of Axon Enterprise, Inc $AXON

Legal & General Group Plc increased its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 3.1% during the third quarter, Holdings Channel reports. The institutional investor owned 421,114 shares of the biotechnology company’s stock after purchasing an additional 12,736 shares during the quarter. Legal & General Group Plc’s holdings in Axon Enterprise were worth $302,208,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC acquired a new position in Axon Enterprise in the 4th quarter valued at approximately $480,000. NewEdge Advisors LLC grew its holdings in shares of Axon Enterprise by 41.1% during the 1st quarter. NewEdge Advisors LLC now owns 2,294 shares of the biotechnology company’s stock worth $1,207,000 after purchasing an additional 668 shares in the last quarter. Empowered Funds LLC increased its position in shares of Axon Enterprise by 8.4% during the first quarter. Empowered Funds LLC now owns 2,028 shares of the biotechnology company’s stock valued at $1,067,000 after purchasing an additional 157 shares during the period. Woodline Partners LP increased its position in shares of Axon Enterprise by 40.6% during the first quarter. Woodline Partners LP now owns 6,932 shares of the biotechnology company’s stock valued at $3,646,000 after purchasing an additional 2,003 shares during the period. Finally, Sivia Capital Partners LLC acquired a new position in shares of Axon Enterprise in the second quarter valued at $284,000. 79.08% of the stock is currently owned by institutional investors.

Key Stories Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Recent operating momentum and scale: company commentary and filings highlighted robust device and software demand, rising ARR/bookings and accelerating revenue that underpinned the prior rally. Axon slips as investors digest rich valuation after a sharp post-earnings run-up
• Positive Sentiment: Analyst backing and price-target runway: multiple firms maintain buy/overweight ratings and the median 6‑month target sits well above current levels, giving upside for longer-term holders. Axon slips as investors digest rich valuation after a sharp post-earnings run-up
• Positive Sentiment: Momentum recap: AXON had climbed nearly 29% over the prior month on strong device/software demand — a factor that supports the bull case if execution continues. Axon Stock Rises 28.6% in a Month: Should Investors Buy or Wait?
• Neutral Sentiment: No meaningful short-interest signal (data shows zero or NaN) — likely a reporting anomaly, so it shouldn’t be interpreted as a fresh bearish catalyst.
• Neutral Sentiment: Third‑party/industry headlines referencing “Axon” (e.g., AppLovin’s “Axon by AppLovin” product and related studies) are unrelated to Axon Enterprise’s business and can confuse coverage — treat those items as industry noise. AppLovin (APP) Is Up 19.5% After Showcasing AXON 2.0 And AI E-commerce Pivot
• Negative Sentiment: Profit‑taking and valuation sensitivity: analysts and market commentary point to a classic post‑earnings retracement after a fast run; high valuation metrics make the stock susceptible to short‑term pullbacks. Axon slips as investors digest rich valuation after a sharp post-earnings run-up
• Negative Sentiment: Heavy insider selling noted in recent disclosures increases near‑term perceived risk and can sap sentiment even if proceeds are routine. Axon slips as investors digest rich valuation after a sharp post-earnings run-up
• Negative Sentiment: Relative underperformance vs. peers on the day added selling pressure, suggesting short‑term rotation rather than a fresh fundamental shift. Axon Enterprise Inc. stock underperforms Tuesday when compared to competitors

Axon Enterprise Stock Down 2.3%

AXON opened at $517.57 on Thursday. The firm’s 50-day simple moving average is $533.80 and its 200-day simple moving average is $613.08. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.29 and a current ratio of 2.53. Axon Enterprise, Inc has a twelve month low of $396.41 and a twelve month high of $885.91. The firm has a market cap of $41.61 billion, a price-to-earnings ratio of 340.51, a PEG ratio of 11.31 and a beta of 1.46.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.55. The business had revenue of $796.72 million during the quarter, compared to analysts’ expectations of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The firm’s revenue for the quarter was up 38.5% on a year-over-year basis. During the same quarter last year, the company posted $2.08 EPS. Equities research analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Robert W. Baird set a $800.00 target price on Axon Enterprise in a research report on Wednesday, February 25th. William Blair reissued an “outperform” rating on shares of Axon Enterprise in a report on Tuesday, February 3rd. UBS Group dropped their price objective on shares of Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating for the company in a research note on Wednesday, February 25th. Northcoast Research raised shares of Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 price objective for the company in a report on Tuesday, January 6th. Finally, Barclays decreased their target price on shares of Axon Enterprise from $702.00 to $682.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. Sixteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $762.93.

Insider Transactions at Axon Enterprise

In other news, CEO Patrick W. Smith sold 10,000 shares of Axon Enterprise stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $500.24, for a total value of $5,002,400.00. Following the completion of the transaction, the chief executive officer owned 3,090,997 shares in the company, valued at approximately $1,546,240,339.28. The trade was a 0.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Isaiah Fields sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $535.01, for a total value of $1,070,020.00. Following the completion of the transaction, the insider directly owned 55,588 shares in the company, valued at $29,740,135.88. The trade was a 3.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 24,634 shares of company stock valued at $13,803,095. Corporate insiders own 4.40% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.